Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Assertio Holdings Inc (NASDAQ: ASRT) recently announced it has reached a definitive acquisition agreement with Gardas.

Assertio Holdings Inc (NASDAQ: ASRT) recently announced it has reached a definitive acquisition agreement with Gardas.

老虎证券老虎证券2026/04/21 21:08
Show original
According to the terms of the agreement, Gardas will acquire all outstanding shares of Assertio at a cash price of $18 per share, with a total transaction value of $125.1 million. The acquisition also includes Contingent Value Rights (CVR), offering shareholders the potential for additional benefits. This strategic acquisition is expected to integrate the strengths and resources of both companies, creating synergy effects. Upon completion of the transaction, Assertio will become a wholly owned subsidiary of Gardas and will continue to operate in its specialized field. The boards of directors of both parties have unanimously approved the transaction and are currently advancing the related regulatory approval processes as planned.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million

Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.

智通财经•2026/10/09 07:11

Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.

Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.

智通财经•2026/10/09 07:09

Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.

Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.

智通财经•2026/10/09 07:08